Search | IOVS | ARVO Journals

View

Showing 1 – 4 of 4

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2015

Gene therapy treatment with AAV-soluble Fas ligand protects retinal ganglion cells during development of Glaucoma

Anitha Krishnan; Fei Fei; Alexander Jones; Bruce R Ksander; Ann Marshak Rothstein; Meredith S Gregory-Ksander

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):2594. doi:

ARVO Annual Meeting Abstract April 2014

Soluble Fas ligand is a neuroprotective molecule critical in restricting glaucomatous damage to retinal ganglion cells

Anitha Krishnan; Alexander Jones; Ann Marshak Rothstein; Bruce R Ksander; Meredith S Gregory-Ksander

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):2194. doi:

ARVO Annual Meeting Abstract April 2011

Accelerated Glaucoma And Increased Neurotoxicity In DBA/2J Mice That Cannot Cleave Fas Ligand

Bruce R. Ksander; Alexander Jones; Simon W. John; Ann Marshak-Rothstein; Meredith S. Gregory

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):2449. doi:

ARVO Annual Meeting Abstract April 2011

sGCα1-Deficient Mice: A Novel Murine Model Of Spontaneous Primary Open Angle Glaucoma

Emmanuel S. Buys; Sarah Hayton; Alexander Jones; Yu-Chieh Ko; Meredith Gregory; Haiyan Gong; Peter Brouckaert; Louis R. Pasquale; Kenneth D. Bloch; Bruce Ksander

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):5880. doi:

Advertisement